Adoptive cell transfer of murine p50-IMC, following a dose of 5FU, activates tumor myeloid and T cells to slow tumor growth and predicts the therapeutic utility of human p50-IMC against multiple solid tumors. The gene discussed is CD40; the disease is neoplasm.